K2K ★ India, 2013-10-18 12:05 (4226 d 05:40 ago) Posting: # 11691 Views: 8,392 |
|
Dear All, As Per the FDA Draft Guideline (Additional Comments: Applicants may consider using a reference-scaled average bioequivalence approach. Please refer to Progesterone Capsules Guidance for information regarding statistical analysis method using the reference scaled average bioequivalence approach) We Plan to conduct the pilot Study with 2 test formulation. So Pls suggest me which design is suitable. Design 1: Williams’ design with T1 = test 1, T2 = test 2, R =reference (6 sequence, 3 treatment and 3 period) or Design 2: Partial replicate design (T1, T2 and R (2 times)) with Four Sequence, Four Period, Three treatment. (Crossover design for four medications (Williams’ design)) 1 R T2 R T1 Whether its possible to do Partial Replicate design like this. Pls suggest me which design is suitable. Thanks and Regards k2k Edit: Category changed. [Helmut] |
vinayshed ☆ 2013-10-28 09:42 (4216 d 07:03 ago) @ K2K Posting: # 11788 Views: 7,016 |
|
Since you want reference scaled study and have two formulations, you can to use R R T1 T2 for your pilot study. Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Dr_Dan] Please see the Forum’s Policy. |
Helmut ★★★ ![]() ![]() Vienna, Austria, 2013-10-28 13:11 (4216 d 03:34 ago) @ vinayshed Posting: # 11792 Views: 7,029 |
|
Dear Vinay, ❝ Since you want reference scaled study and have two formulations, you can to use R R T1 T2 for your pilot study. Are you serious? — Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |
vinayshed ☆ 2013-10-28 15:47 (4216 d 00:58 ago) @ Helmut Posting: # 11795 Views: 6,989 |
|
Does he/she have any other option? |
Helmut ★★★ ![]() ![]() Vienna, Austria, 2013-10-28 16:09 (4216 d 00:36 ago) @ vinayshed Posting: # 11797 Views: 6,982 |
|
Dear Vinay, ❝ Does he/she have any other option? Your design is not randomized and therefore, period effects are not accounted for. Maybe somebody else can come up with a suitable design. PS: Please follow the Forum’s Policy as Dr. Dan already suggested. If you prefer laconic statements, consider joining Twitter instead. — Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |
K2K ★ India, 2013-10-29 11:10 (4215 d 05:35 ago) @ Helmut Posting: # 11802 Views: 6,983 |
|
Dear Helmut, ❝ Your design is not randomized and therefore, period effects are not accounted for. How its not accounted for period effects? As per the Link http://forum.bebac.at/mix_entry.php?id=10358 Mr. d_labes suggested sequence for the same but sequence as changed little bit. Shall i consider this sequence or not. Thanks and Regards K2k |
Helmut ★★★ ![]() ![]() Vienna, Austria, 2013-10-29 14:14 (4215 d 02:31 ago) @ K2K Posting: # 11803 Views: 6,963 |
|
Hi K2k, ❝ How its not accounted for period effects? Again: Vinay’s infamous RRT1T2 is not randomized!Imagine you have period effects of ±0, +20, +15, –10% and ‘true’ bioequivalence of both formulations, i.e., T1=T2=R=1. Responses in the four periods are expected to be P1=1+0=1, P2=1+1×20%=1.20, P3=1+1×15%=1.15, and P4=1–1×10%=0.90. Estimated treatment effects will be R=(P1+P2)/2=(1+1.20)/2=1.10, T1=P3=1.15, and T2=P4=0.90. GMRs will be T1/R=1.15/1.10=104.55% and T2/R=0.90/1.10=81.82%. That’s not the 100% we expect (biased due to lacking randomization). Any cross-over design which is not randomized & balanced for treatments within periods cannot give unbiased treatment effects. ❝ As per the Link http://forum.bebac.at/mix_entry.php?id=10358 Mr. d_labes suggested sequence for the same but sequence as changed little bit. If you have read the entire thread (and the linked references) you would have noticed that it is not that easy. ❝ Shall i consider this sequence or not. Never apply anything you don’t completely comprehend. PS: To quote Detlew: “I myself would not go with such a design due to the uncertainties involved.” PPS: What if both tests have similar GMRs? With which one would you perform the pivotal study? Would be nice to get some information about the products’ variances. Maybe we can work in the spirit of Balaam’s design?
Though I have some ideas… Homework/exercise: Is the design balanced for period effects? And for carry-over? Why don’t you simply run two separate fully replicated three period studies – and tell us afterwards how much CVWR differed between the two?
— Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |
K2K ★ India, 2013-10-31 11:08 (4213 d 05:37 ago) @ Helmut Posting: # 11835 Views: 6,775 |
|
Dear Helmut, ❝ Why don’t you simply run two separate fully replicated three period studies – and tell us afterwards how much CVWR differed between the two? ❝ ❝ After Completion of Study I will Share the CVWR. Thanks for your valuable suggestions. Thanks and Regards K2k |
Helmut ★★★ ![]() ![]() Vienna, Austria, 2013-10-31 17:25 (4212 d 23:20 ago) @ K2K Posting: # 11845 Views: 6,792 |
|
Hi K2k, ❝ After Completion of Study I will Share the CVWR. Even if you tell us the drug / reference formulation I have limited interest in that. Would only be nice to compare the CVWR from two different studies (same site / design / sample size). — Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |